OncoMatch/Clinical Trials/NCT06740019
A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
Is NCT06740019 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies JMKX000197 for malignant pleural effusions (mpe).
Treatment: JMKX000197 — A Phase Ib Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: STING agonist
Have used interferon gene stimulating factor (STING) agonists for pleural perfusion
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06740019 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior STING agonist disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify